Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel E Furst

Showing results (401-410 of 477) with videos related to

Pageof 48
Sort By:
Seminars in Arthritis and Rheumatism|February 24, 2004
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learnedPhilip J Clements, James R Seibold, Daniel E Furst, et al.
Annals of the Rheumatic Diseases|February 4, 2019
Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018Kevin L Winthrop, Michael E Weinblatt, Mary K Crow, et al.
Journal of Scleroderma and Related Disorders|August 25, 2025
Treatment recommendations for the systemic pharmacological treatment of systemic sclerosis digital ulcers: Results from the World Scleroderma Foundation Ad Hoc CommitteeNancy Maltez, Laura Ross, Murray Baron, et al.
The Lancet. Rheumatology|January 24, 2024
Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohortMuriel Elhai, Nanthara Sritharan, Marouane Boubaya, et al.
Annals of the Rheumatic Diseases|August 9, 2019
Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signaturesShervin Assassi, Xuan Wang, Guocai Chen, et al.
Annals of the Rheumatic Diseases|October 26, 2017
Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)Dinesh Khanna, Christopher P Denton, Celia J F Lin, et al.
Arthritis and Rheumatism|December 30, 2006
Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192Christopher P Denton, Peter A Merkel, Daniel E Furst, et al.
Blood|August 15, 2002
High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomesPeter A McSweeney, Richard A Nash, Keith M Sullivan, et al.
Arthritis and Rheumatism|July 13, 2002
Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritisTino Munster, John P Gibbs, Danny Shen, et al.
Annals of the Rheumatic Diseases|September 1, 2010
Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trialMarco Matucci-Cerinic, Christopher P Denton, Daniel E Furst, et al.
Pageof 48

Showing results (401-410 of 477) with videos related to

Sort By:
Pageof 48
Seminars in Arthritis and Rheumatism|February 24, 2004
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learnedPhilip J Clements, James R Seibold, Daniel E Furst, et al.
Annals of the Rheumatic Diseases|February 4, 2019
Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018Kevin L Winthrop, Michael E Weinblatt, Mary K Crow, et al.
Journal of Scleroderma and Related Disorders|August 25, 2025
Treatment recommendations for the systemic pharmacological treatment of systemic sclerosis digital ulcers: Results from the World Scleroderma Foundation Ad Hoc CommitteeNancy Maltez, Laura Ross, Murray Baron, et al.
The Lancet. Rheumatology|January 24, 2024
Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohortMuriel Elhai, Nanthara Sritharan, Marouane Boubaya, et al.
Annals of the Rheumatic Diseases|August 9, 2019
Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signaturesShervin Assassi, Xuan Wang, Guocai Chen, et al.
Annals of the Rheumatic Diseases|October 26, 2017
Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)Dinesh Khanna, Christopher P Denton, Celia J F Lin, et al.
Arthritis and Rheumatism|December 30, 2006
Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192Christopher P Denton, Peter A Merkel, Daniel E Furst, et al.
Blood|August 15, 2002
High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomesPeter A McSweeney, Richard A Nash, Keith M Sullivan, et al.
Arthritis and Rheumatism|July 13, 2002
Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritisTino Munster, John P Gibbs, Danny Shen, et al.
Annals of the Rheumatic Diseases|September 1, 2010
Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trialMarco Matucci-Cerinic, Christopher P Denton, Daniel E Furst, et al.
Pageof 48